Show simple item record

dc.contributor.authorPhillips, EH
dc.contributor.authorBurton, C
dc.contributor.authorKirkwood, AA
dc.contributor.authorBarrans, S
dc.contributor.authorLawrie, A
dc.contributor.authorRule, Simon
dc.contributor.authorPatmore, R
dc.contributor.authorPettengell, R
dc.contributor.authorArdeshna, KM
dc.contributor.authorMontoto, S
dc.contributor.authorPaneesha, S
dc.contributor.authorClifton‐Hadley, L
dc.contributor.authorLinch, DC
dc.contributor.authorMcMillan, AK
dc.date.accessioned2022-02-17T14:09:46Z
dc.date.available2022-02-17T14:09:46Z
dc.date.issued2020-04-29
dc.identifier.issn2688-6146
dc.identifier.issn2688-6146
dc.identifier.urihttp://hdl.handle.net/10026.1/18816
dc.description.abstract

<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Outcomes after frontline treatment of Burkitt lymphoma (BL) have improved with the introduction of dose‐intense chemotherapy regimens, such as CODOX‐M/IVAC. While rituximab has increased survival rates for most forms of high‐grade B‐cell lymphoma, there has previously been hesitancy about incorporating it into BL treatment, partly due to concerns about increased toxicity. Prospective data using the standard dose CODOX‐M/IVAC regimen in combination with rituximab are lacking. We conducted a single‐arm phase 2 trial to assess the efficacy and toxicity of R‐CODOX‐M/R‐IVAC.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Eligible patients were aged 18–65 years, with newly diagnosed BL with <jats:italic>MYC</jats:italic> rearrangement as the sole cytogenetic abnormality, and high‐risk disease, defined by an International Prognostic Index (IPI) score of 3‐5. Patients received two cycles of R‐CODOX‐M chemotherapy alternating with two cycles of R‐IVAC, followed by two further cycles of rituximab alone. The primary endpoint was 2‐year progression‐free survival.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Thirty‐eight patients were registered but after central pathology review, 27 patients had confirmed BL and commenced study treatment. Median age was 35 years, 14.8% patients had central nervous system involvement and 18.5% were HIV positive. Twenty‐two (81.4%) patients completed four cycles of chemotherapy. There were two treatment‐related deaths (7.4%). Two‐year progression‐free and overall survival rates were 77.2% (90% confidence interval [CI]: 56.0‐89.0) and 80.7% (90% CI: 59.6‐91.5), respectively.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This prospective trial demonstrates excellent survival rates with R‐CODOX‐M/R‐IVAC in a high‐risk BL cohort. It provides reassuring evidence regarding the feasibility of this regimen and also provides a benchmark for future studies.</jats:p></jats:sec>

dc.format.extent133-141
dc.format.mediumElectronic-eCollection
dc.languageen
dc.language.isoen
dc.publisherWiley
dc.subjectCNS
dc.subjectHIV
dc.subjectchemotherapy
dc.subjectimmunotherapy
dc.subjectlymphomas
dc.subjectmonoclonal antibodies
dc.titleFavourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
dc.typejournal-article
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35847742
plymouth.issue1
plymouth.volume1
plymouth.publication-statusPublished
plymouth.journaleJHaem
dc.identifier.doi10.1002/jha2.3
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeUnited States
dcterms.dateAccepted2020-03-12
dc.rights.embargodate2022-2-18
dc.identifier.eissn2688-6146
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1002/jha2.3
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2020-04-29
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV